Neurologic complications of chemotherapy agents.
OBJECTIVE
To review neurologic complications of common and recently developed chemotherapeutic agents, as well as recent research regarding 'chemobrain'.


RESULTS
Bortezomib, a new anticancer agent, has a propensity toward causing a largely sensory and reversible peripheral neuropathy. Infusion of magnesium and calcium pre and post-oxaliplatin infusion reduces neuropathy but may interfere with clinical response to oxaliplatin. No other measures currently reduce the incidence or severity of neuropathy related to platinum compounds, taxanes, or thalidomide. Chemobrain, cognitive decline attributed to chemotherapy, has garnered research interest. Prevalence and epidemiology of chemobrain are poorly understood. Potential underlying mechanisms are under investigation in animal models and include effects on long-term potentiation and cerebral blood flow. Blood-brain barrier permeability, efficiency of cellular efflux pumps, DNA damage, telomere shortening, alteration of cytokine regulation, defects in neural repair, and oxidative stress may play roles in the effects of chemotherapy on central nervous system function.


CONCLUSIONS
Data on prevention and treatment of chemotherapy-induced peripheral neuropathy are limited. Calcium and magnesium infusions for oxaliplatin administration have the most scientific support and are widely used in practice but may interfere with the clinical efficacy of oxaliplatin. Some novel agents, particularly bortezomib, have significant risk of chemotherapy-induced peripheral neuropathy. Animal models are beginning to reveal the mechanisms underlying the impact of individual chemotherapeutic drugs on cognition.
Kannarkat
George
G
Division of Hematology-Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia 22908-0432, USA.
Lasher
Erin E
EE
Schiff
David
D
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001932:Brain Neoplasms / Q000188:drug therapy*; D002118:Calcium / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology
D000970:Antineoplastic Agents; D008274:Magnesium; D002118:Calcium